Amantadine Discontinuation: No Specific Taper Schedule Recommended
There is no established taper schedule for discontinuing amantadine in the available FDA labeling or clinical guidelines. The FDA-approved prescribing information does not provide specific tapering instructions for amantadine discontinuation 1.
Key Guidance from FDA Labeling
The FDA drug label addresses dose reduction in specific clinical scenarios but does not mandate tapering:
- For Parkinson's disease patients experiencing loss of effectiveness: The label mentions "temporary discontinuation of amantadine hydrochloride for several weeks, followed by reinitiation of the drug, may result in regaining benefit" 1
- No explicit taper protocol is provided for routine discontinuation
Critical Safety Consideration: Neuroleptic Malignant Syndrome Risk
The most important clinical concern is the risk of severe hyperthermia and neuroleptic malignant syndrome-like reactions with abrupt withdrawal, particularly in Parkinson's disease patients. One case series documented two patients who developed severe hyperthermia (39-40°C) after abrupt amantadine withdrawal 2. When amantadine was reintroduced and then tapered over 15 days, no further adverse reactions occurred 2.
Practical Approach Based on Available Evidence
Given the documented risk of severe withdrawal reactions:
- Avoid abrupt discontinuation, especially in patients taking amantadine for Parkinson's disease or at higher doses (≥200 mg/day)
- A gradual taper over 1-2 weeks appears reasonable based on the single case report showing successful tapering over 15 days 2
- Monitor closely for hyperthermia, rigidity, altered consciousness, and autonomic instability during and after discontinuation
- Consider slower tapers (several weeks) for patients on long-term therapy or higher doses
Context-Specific Considerations
For influenza prophylaxis/treatment: The guidelines indicate treatment should continue for 24-48 hours after symptom resolution 3, suggesting abrupt discontinuation may be acceptable in this short-term use context.
For Parkinson's disease: Given the documented risk of severe withdrawal reactions and the chronic nature of therapy, a more cautious approach with gradual dose reduction is warranted 2.
Dose adjustments during therapy (not discontinuation): The FDA label provides clear guidance for dose reduction in renal impairment, elderly patients, and those experiencing side effects, but these are maintenance dose adjustments rather than discontinuation protocols 1.
Common Pitfall
The primary pitfall is abrupt discontinuation without monitoring, particularly in Parkinson's disease patients who may develop life-threatening hyperthermia. If withdrawal symptoms develop, consider reintroducing amantadine and implementing a slower taper 2.